City

Houston (1)

Portland (1)

Overall Status

Recruiting (2)

Phase

phase 1 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

Providence Health & Services (1)

Collaborator

Bristol-Myers Squibb (1)

Exelixis (1)

National Cancer Institute (NCI) (1)

Intervention

cabozantinib (1)

cord blood-derived expanded allogeneic natural killer cells (1)

cyclophosphamide (1)

etoposide (1)

ipilimumab (1)

nivolumab (1)

Study Documents

Intervention Type

drug (2)

biological (1)

Funder Type

Other (2)

Study Type

Interventional (2)

refractory cutaneous melanoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Refractory Cutaneous Melanoma Trial in Portland (Ipilimumab, Nivolumab, Cabozantinib)

Recruiting

Refractory Cutaneous Melanoma

Ipilimumab
+2 more

Portland, Oregon

Providence Portland Medical Center

Jun 8, 2022

Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Tumor Trial in Houston

Recruiting

Recurrent Cutaneous Melanoma
+27 more

Cord Blood-derived Expanded Allogeneic Natural Killer Cells
+2 more

Houston, Texas

M D Anderson Cancer Center

Apr 28, 2021